These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 32053311)
41. Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation. Sermet-Gaudelus I; Delion M; Durieu I; Jacquot J; Hubert D J Cyst Fibros; 2016 Nov; 15(6):e67-e69. PubMed ID: 27745802 [TBL] [Abstract][Full Text] [Related]
42. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE; J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799 [TBL] [Abstract][Full Text] [Related]
43. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation. Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984 [TBL] [Abstract][Full Text] [Related]
44. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation. McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768 [TBL] [Abstract][Full Text] [Related]
45. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies. McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001 [TBL] [Abstract][Full Text] [Related]
46. Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent. Van der Plas SE; Kelgtermans H; De Munck T; Martina SLX; Dropsit S; Quinton E; De Blieck A; Joannesse C; Tomaskovic L; Jans M; Christophe T; van der Aar E; Borgonovi M; Nelles L; Gees M; Stouten P; Van Der Schueren J; Mammoliti O; Conrath K; Andrews M J Med Chem; 2018 Feb; 61(4):1425-1435. PubMed ID: 29148763 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA; Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085 [TBL] [Abstract][Full Text] [Related]
48. Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion. Colombo C; Foppiani A; Bisogno A; Gambazza S; Daccò V; Nazzari E; Leone A; Giana A; Mari A; Battezzati A J Endocrinol Invest; 2021 Oct; 44(10):2213-2218. PubMed ID: 33586024 [TBL] [Abstract][Full Text] [Related]
49. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Wainwright CE; Elborn JS; Ramsey BW N Engl J Med; 2015 Oct; 373(18):1783-4. PubMed ID: 26510034 [No Abstract] [Full Text] [Related]
50. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Rehman A; Baloch NU; Janahi IA N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035 [No Abstract] [Full Text] [Related]
51. Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor: Experience of the regional referral center in Tuscany, Italy. Manciulli T; Bresci S; Mencarini J; Avarello A; Taccetti G; Terlizzi V Pediatr Pulmonol; 2023 Dec; 58(12):3626-3629. PubMed ID: 37750598 [No Abstract] [Full Text] [Related]
52. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results. Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946 [TBL] [Abstract][Full Text] [Related]
53. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy. Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933 [TBL] [Abstract][Full Text] [Related]
54. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Strug LJ; Gonska T; He G; Keenan K; Ip W; Boëlle PY; Lin F; Panjwani N; Gong J; Li W; Soave D; Xiao B; Tullis E; Rabin H; Parkins MD; Price A; Zuberbuhler PC; Corvol H; Ratjen F; Sun L; Bear CE; Rommens JM Hum Mol Genet; 2016 Oct; 25(20):4590-4600. PubMed ID: 28171547 [TBL] [Abstract][Full Text] [Related]
56. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis. Middleton PG; Taylor-Cousar JL Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928 [No Abstract] [Full Text] [Related]
57. Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis. Hudson BN; Jacobs HR; Philbrick A; Zhou XA; Simonsen MM; Safirstein JA; Rotolo SM J Cyst Fibros; 2022 Nov; 21(6):1066-1069. PubMed ID: 36088208 [TBL] [Abstract][Full Text] [Related]
58. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor. Munce D; Lim M; Akong K Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556 [TBL] [Abstract][Full Text] [Related]
59. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]